摘要
目的：评价马蔺子素胶囊对头颈、胸部肿瘤放疗治疗的增敏作用及毒副反应。方法：1880例经病理确诊的肿瘤病人被随机地分为治疗组和对照组，两组病人均采用相同的设野和放射剂量。治疗组在放疗的同时给予140mg（M2·d），对照组单纯放疗。采用增敏比（ER）和肿瘤的局部控制率（CR，或CR＋PR）作为增敏的评价指标。结果：治疗组和对照组病人临床特征均无差别。治疗组中鼻咽癌、头颈癌病人的原发灶达到PR和CR的平均放疗剂量、治疗结束时的CR率，均优于对照组，增敏比为1．06～1．28；治疗组肺癌和食道癌病人原发灶半量放疗的有效率比对照组明显为优（67．52％比45．58％和52．32比25．31％），全量放疗结束时的CR率亦较对照组明显提高（36．04％比10．23％和50．77％比23．13％），在转移灶方面，显示治疗组鼻咽癌人转移灶达到PR和CR的平均放疗剂量、治疗结束时的CR率，均优于对照组，增敏比为1．05～1．27；内脏肿瘤中治疗组肺癌病人转移灶的半量有效率和全消率均优于对照组。在毒性反应方面，治疗组在消化道方面的毒副反应如恶心、呕吐、腹泻等较对照组多。结论：该药对鼻咽癌、头颈癌、肺癌和食道癌原发灶和鼻咽癌、肺癌的转移灶均具有放射增敏作用。本次观察只限临床近期疗效的比较。
Purpose:A prospective clinical trial was conducted to evaluate the radiosensitive effect and the toxicity of Irisquinones(Iq7611) in the treatment of non-small cell lung cancer(NSCLC), esophagus carcinoma, head and neck cancer (HNC), nasopharyngeal carcinoma (NPC). Method and Materials: 1880 cases Of pathological proven malignancies were randomized divided into study group or control group. The dosage and method of radiation are identical in the two groups. For the study group, patients were treated with radiotherapy combined lrisquinones 140 mg(M2·d). Patients in the control group received radiotherapy alone. Enhancement Ratio (ER) and local control of primal and metastatic disease severed as target for evaluating the radioseneitive effect of this drug. Result: 510 cases of NPC, 106 cases of HNC, 412cases of NSCLC, 643 cases of esophagus carcinoma and 209 cases of other malignancies were treated. The patient's characteristics were similar in both arm. For patients with NPC and HNC in study group, average PR and CR radiation dosage.CR rate of primary disease were superior than that in control group. Enhancement Ration ranged between 1. 06 to 1. 28; For patients with NSCLC and esophagus carcinoma, the response of half dosage (67. 52% v 45. 58% and 52. 32% v 25. 31%)and CR rate (36.04% v 10. 23% and 50. 77% v 23. 13% ) of primary disease were also superior in study group compared with control group. In study group, average PR and CR radiation dosage. CR rate of NPC metastatic disease were better than in control group. Enhancement Ratio (ER) were 1. 05~1. 27 (for NPC metastatic disease). The response of metastatic disease for NSCLC patients were better in study group than in control group. Patients in study group had more gastrointestinal side-effects such as nausea, vomiting and diarrhea, but the side-effects were mild and well tolerated. Conclusion:Thisstudy confirmed that Irisquinones (Iq7611) has radiosensitive effect in the treatment of primacy tumor for patients with NPC,HNC, NSCLC and esophagus carcinoma as well as in the treatment of metastatic disease for patients with NPC and NSCLC.However, the role of combine radiotherapy and Iq7611 on long term survival remains to be answered.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1999年第1期52-55,共4页
Chinese Journal of Cancer
